Orion
Tuomo Kalliokoski is an accomplished expert in Computational Pharmacology and Computer-Aided Drug Design (CADD), currently serving as an Adjunct Professor at the University of Eastern Finland since October 2020. Holding a Senior Scientist position at Orion Corporation since January 2017, Tuomo Kalliokoski has contributed significantly to the fields of pharmacology and medicine design. Previously, Tuomo Kalliokoski held roles such as Computational Scientist at Lead Discovery Center GmbH and Presidential Postdoctoral Fellow at Novartis, specializing in ligand-based virtual screening methods and chemogenomics. With a strong educational background, Tuomo Kalliokoski earned a PhD in Pharmaceutical Chemistry from the University of Eastern Finland, completing the degree in 2010.
Orion
1 followers
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.